<DOC>
	<DOCNO>NCT02063230</DOCNO>
	<brief_summary>A study ass pharmacokinetics , safety tolerability Selumetinib ( AZD6244 , ARRY-142886 ) patient hepatic impairment healthy subject .</brief_summary>
	<brief_title>To Assess Pharmacokinetics , Safety Tolerability Selumetinib Patients With Hepatic Impairment Healthy Subjects</brief_title>
	<detailed_description>An open label study ass pharmcokinetics , safety tolerability single dose Selumetinib ( AZD6244 , ARRY-142886 ) patient hepatic impairment healthy subject .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Inclusion Criteria participant : 1 . Subjects male female ( nonchildbearing potential ) age 18 year weight least 45 kg BMI 18 40 kg/m2 inclusive . Inclusion Critera hepatic impair patient : 2 . Subjects stable liver cirrhosis hepatic impairment least 3 month prior start study . Inclusion Criteria healthy volunteer : 3 . Subjects must good health , determine medical history , physical examination , 12lead ECG , clinical laboratory evaluation , ophthalmic examination perform administration investigational product . Exclusion Criteria participant : 1 . Subjects Japanese nonJapanese Asian ethnicity 2 . Any one parent grandparent ( maternal paternal ) Japanese nonJapanese Asian ( eg , China , Taiwan , Korea , Philippines , Thailand , Vietnam , Malaysia ) . Asian Indians acceptable . 3 . Any clinically important illness , medical/surgical procedure , trauma within 4 week first administration investigational product 4 . Subjects smoke 10 cigarette equivalent tobacco per day . Exclusion criterion hepatic impair patient 5 . Undergone liver transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Phase I , healthy , pharmacokinetic , hepatic impairment</keyword>
</DOC>